A single company has emerged as the frontrunner in the race to develop blood tests that detect cancer recurrence in survivors. Wall Street investors are placing significant bets on this technology, which promises to identify returning tumors earlier than current methods. The tests, known as liquid biopsies, analyze blood for traces of cancer DNA.
The company generating this interest is Guardant Health, which already has a test on the market for advanced cancer patients. Its new test targets earlier-stage disease, aiming to catch residual cancer cells left after treatment. Early detection of recurrence could dramatically improve survival rates.
Current surveillance methods, such as CT scans, often miss small tumors or yield false positives. Liquid biopsies offer a less invasive alternative, requiring only a simple blood draw. This convenience could lead to more frequent monitoring and faster clinical responses.
Guardant Health’s test, called Guardant Reveal, has shown promising results in early studies. It detected cancer DNA in patients who were deemed cancer-free by traditional imaging. The company is now conducting larger trials to confirm these findings and seek regulatory approval.
The market potential is enormous, with millions of cancer survivors in the United States alone. Investors see a recurring revenue stream from tests performed multiple times per year. This has driven Guardant’s stock price higher, despite the company still reporting net losses.
Competitors are also active in this space, including Natera and Exact Sciences. However, Guardant’s early lead and robust data have given it a distinct advantage. The company plans to expand its test to cover multiple cancer types.
Regulatory hurdles remain, as the tests must prove they improve patient outcomes. The Food and Drug Administration has yet to approve a liquid biopsy for cancer recurrence surveillance. Guardant expects to submit its data for review within the next year.
If successful, these tests could transform post-treatment care for cancer patients. They would provide a simple, accurate way to monitor for recurrence without invasive procedures. Wall Street is betting that Guardant will be the one to deliver this change.
